Cytogenix (fka CYGX)

[Jimmy Joe]

In answer to your reply:

My reply.

FORM 8-K Report of unscheduled material events or corporate changes.

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

-------------------------------------------------------

Why would you as a company divulge what you are charging a partner you are also in COLLABORATION with in R&D for DNA vaccines?
Now for the sake of argument let us say that Aldevron is getting a price break. Hell we know they are. Let us say that a potential customer other than Aldevron was getting charged more money found out how much Aldevron paid but wants the same break Aldevron got.
Does that make good business sense?
That is why I feel strongly that what Aldevron paid is between Aldevron and Cytogenix and is none of the shareholders business. The quarterly report will show all that needs to be shown when the time comes. If CYGX management is breaching their fiduciary responsibilities by occluding the numbers from an 8K the SEC should be contacted. But I doubt that is the case.

Too many questions. Way too many. And at a point where Cytogenix and management are definitely in the drivers seat.
NOTHING seems to satisfy. Why?

JJM